Please ensure Javascript is enabled for purposes of website accessibility

Why Teladoc Stock Soared 25% in July but Is Down 19% in August

By Beth McKenna – Aug 9, 2020 at 12:57PM

You’re reading a free article with opinions that may differ from The Motley Fool’s Premium Investing Services. Become a Motley Fool member today to get instant access to our top analyst recommendations, in-depth research, investing resources, and more. Learn More

This virtual healthcare leader's business is getting a boost from the COVID-19 pandemic, but investors don't like its acquisition plans.

What happened

Shares of telehealth leader Teladoc Health (TDOC -3.40%) surged 24.5% in July, according to data from S&P Global Market Intelligence. For context, the S&P 500 returned 5.6% last month.

However, the stock has given back most of July's gain already this month. It fell 18.5% in the first week of August. Nonetheless, it's still up a whopping 131% so far in 2020, compared with the broader market's 4.9% return, making it a top performer among large caps (stocks with market caps of at least $10 billion).

Person's hands holding a cell phone which has a young male doctor on the screen.

Images source: Getty Images.

So what


We can attribute Teladoc stock's strong performance last month in part to a continuation of the momentum it's experienced since earlier this year, driven by the COVID-19 pandemic. The crisis has caused a surge in the number of people consulting with healthcare providers virtually rather than in person.

There was also a specific catalyst last month: The company's July 29 release of second quarter results that pleased investors. Shares popped 8.6% the following day.

In the second quarter, Teladoc's sales soared 85% year over year to $241 million, driven by a 203% year over year (and 38% sequential) increase in total visits to more than 2.7 million. Revenue easily topped the $220.7 million Wall Street consensus estimate.

Net loss narrowed 12% to $25.7 million, which translated to net loss per share narrowing 17% to $0.34. Excluding a $0.10 charge associated with the company's May 2020 convertible debt offering, loss per share was $0.24. This result was essentially in line with analysts' expectation of a $0.23 net loss.


We can attribute Teladoc stock's poor start to this month to some investors not being pleased with the company's Aug. 5 acquisition announcement. In an all-stock deal, Teladoc plans to acquire Livongo Health (LVGO), which provides digital tools aimed at helping people with diabetes and other chronic conditions improve their health.

Teladoc stock plunged 19% on the day of the acquisition announcement and moved 22.3% lower in the three-day period (through Friday, Aug. 7) following the news.

There are probably at least a couple reasons for the market's reaction. Some investors might not think the pairing is adequately synergistic, while some don't like that their ownership will be diluted by the issuance of additional shares. 

TDOC Chart

Data source: YCharts.

Now what

For full-year 2020, Teladoc management has guided for total revenue growth of 77% to 80% year over year, which includes organic revenue growth of 65% to 68%. The organic revenue growth forecast doesn't include the contribution from InTouch Health, a hospital-based telemedicine company acquired by Teladoc on July 1.

For 2020, management also expects a loss per share between $1.45 to $1.36, representing loss per share expanding 5% to narrowing 1% from 2019. 

The 2020 total revenue and earnings outlooks don't include the impact from the acquisition of Livongo Health. If this deal goes through and closes by year-end, investors can expect Teladoc management to update its guidance.

Beth McKenna has no position in any of the stocks mentioned. The Motley Fool owns shares of and recommends Livongo Health Inc and Teladoc Health. The Motley Fool has a disclosure policy.

Invest Smarter with The Motley Fool

Join Over 1 Million Premium Members Receiving…

  • New Stock Picks Each Month
  • Detailed Analysis of Companies
  • Model Portfolios
  • Live Streaming During Market Hours
  • And Much More
Get Started Now

Stocks Mentioned

Teladoc Health Stock Quote
Teladoc Health
$27.60 (-3.40%) $0.97
Livongo Health Inc Stock Quote
Livongo Health Inc

*Average returns of all recommendations since inception. Cost basis and return based on previous market day close.

Related Articles

Motley Fool Returns

Motley Fool Stock Advisor

Market-beating stocks from our award-winning analyst team.

Stock Advisor Returns
S&P 500 Returns

Calculated by average return of all stock recommendations since inception of the Stock Advisor service in February of 2002. Returns as of 11/26/2022.

Discounted offers are only available to new members. Stock Advisor list price is $199 per year.

Premium Investing Services

Invest better with The Motley Fool. Get stock recommendations, portfolio guidance, and more from The Motley Fool's premium services.